CTIS2023-503830-27-00招募中1 期
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy - ALLO-647-201
Allogene Therapeutics Inc.0 个研究点目标入组 70 人开始时间: 2023年3月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017, Relapsed or refractory disease after at least 2 lines of chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1., Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening., Adequate hematological function, Adequate Renal Function, Adequate Liver Function
排除标准
- •Active central nervous system (CNS) involvement by malignancy, Hypocellular bone marrow for age, Autologous or allogeneic HSCT within last 6 months (24 weeks) prior to lymphodepletion.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing’s SarcomaMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ewing's SarcomaEUCTR2021-004734-11-DEEli Lilly and Company45
招募中
2 期
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's SarcomaJPRN-jRCT2071220043Masaki Takeshi45
进行中（未招募）
1 期
A medical research evaluating the efficacy of a new medicine (LY2875358), administered alone or in combination with a second drug named Erlotinib, in patients affected by a defined type of lung cancer (MET Biomarker-Positive Non-Small-Cell Lung Cancer) that experienced a disease progression during a previous treatment with Erlotinib.on Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005477-31-ITEli Lilly and Company100
进行中（未招募）
1 期
A medical research evaluating the efficacy of a new medicine (LY2875358), administered alone or in combination with a second drug named Erlotinib, in patients affected by a defined type of lung cancer (MET Biomarker-Positive Non-Small-Cell Lung Cancer) that experienced a disease progression during a previous treatment with Erlotinib.on Small Cell Lung CancerMedDRA version: 16.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005477-31-ESilly S.A.100
进行中（未招募）
1 期
A medical research evaluating the efficacy of a new medicine (LY2875358), administered alone or in combination with a second drug named Erlotinib, in patients affected by a defined type of lung cancer (MET Biomarker-Positive Non-Small-Cell Lung Cancer) that experienced a disease progression during a previous treatment with Erlotinib.on Small Cell Lung CancerMedDRA version: 16.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005477-31-DEEli Lilly and Company100